Logo image of TNYA

TENAYA THERAPEUTICS INC (TNYA) Stock Fundamental Analysis

NASDAQ:TNYA - Nasdaq - US87990A1060 - Common Stock - Currency: USD

0.6832  0 (-0.67%)

After market: 0.7 +0.02 (+2.46%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TNYA. TNYA was compared to 557 industry peers in the Biotechnology industry. While TNYA has a great health rating, there are worries on its profitability. TNYA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TNYA had negative earnings in the past year.
In the past year TNYA has reported a negative cash flow from operations.
TNYA had negative earnings in each of the past 5 years.
In the past 5 years TNYA always reported negative operating cash flow.
TNYA Yearly Net Income VS EBIT VS OCF VS FCFTNYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

TNYA's Return On Assets of -73.47% is on the low side compared to the rest of the industry. TNYA is outperformed by 65.53% of its industry peers.
TNYA has a Return On Equity (-88.58%) which is in line with its industry peers.
Industry RankSector Rank
ROA -73.47%
ROE -88.58%
ROIC N/A
ROA(3y)-69.92%
ROA(5y)-51.76%
ROE(3y)-86.5%
ROE(5y)-62.63%
ROIC(3y)N/A
ROIC(5y)N/A
TNYA Yearly ROA, ROE, ROICTNYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TNYA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNYA Yearly Profit, Operating, Gross MarginsTNYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for TNYA has been increased compared to 1 year ago.
Compared to 5 years ago, TNYA has more shares outstanding
There is no outstanding debt for TNYA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TNYA Yearly Shares OutstandingTNYA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TNYA Yearly Total Debt VS Total AssetsTNYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -4.38, we must say that TNYA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.38, TNYA is in line with its industry, outperforming 41.65% of the companies in the same industry.
There is no outstanding debt for TNYA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.38
ROIC/WACCN/A
WACCN/A
TNYA Yearly LT Debt VS Equity VS FCFTNYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

TNYA has a Current Ratio of 6.68. This indicates that TNYA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TNYA (6.68) is better than 64.99% of its industry peers.
TNYA has a Quick Ratio of 6.68. This indicates that TNYA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TNYA (6.68) is better than 65.17% of its industry peers.
Industry RankSector Rank
Current Ratio 6.68
Quick Ratio 6.68
TNYA Yearly Current Assets VS Current LiabilitesTNYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.27% over the past year.
EPS 1Y (TTM)29.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TNYA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.48% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.95%
EPS Next 2Y20.61%
EPS Next 3Y26.73%
EPS Next 5Y43.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TNYA Yearly Revenue VS EstimatesTNYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
TNYA Yearly EPS VS EstimatesTNYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TNYA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNYA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNYA Price Earnings VS Forward Price EarningsTNYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNYA Per share dataTNYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

TNYA's earnings are expected to grow with 26.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.61%
EPS Next 3Y26.73%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TNYA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TENAYA THERAPEUTICS INC

NASDAQ:TNYA (7/11/2025, 8:00:00 PM)

After market: 0.7 +0.02 (+2.46%)

0.6832

0 (-0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-01 2025-08-01/amc
Inst Owners59.25%
Inst Owner Change0%
Ins Owners0.7%
Ins Owner Change14.69%
Market Cap111.14M
Analysts84
Price Target10.35 (1414.93%)
Short Float %7.38%
Short Ratio4.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.04%
Min EPS beat(2)-23.84%
Max EPS beat(2)11.76%
EPS beat(4)3
Avg EPS beat(4)5.67%
Min EPS beat(4)-23.84%
Max EPS beat(4)19.97%
EPS beat(8)7
Avg EPS beat(8)9%
EPS beat(12)10
Avg EPS beat(12)8.57%
EPS beat(16)11
Avg EPS beat(16)0.69%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-42.21%
EPS NY rev (1m)-1.77%
EPS NY rev (3m)-5.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.93
P/tB 0.93
EV/EBITDA N/A
EPS(TTM)-1.16
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0
BVpS0.73
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.47%
ROE -88.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.92%
ROA(5y)-51.76%
ROE(3y)-86.5%
ROE(5y)-62.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.4%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.68
Quick Ratio 6.68
Altman-Z -4.38
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)115.07%
Cap/Depr(5y)317.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y38.95%
EPS Next 2Y20.61%
EPS Next 3Y26.73%
EPS Next 5Y43.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.93%
EBIT Next 3Y-0.49%
EBIT Next 5Y-12.25%
FCF growth 1Y27.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.82%
OCF growth 3YN/A
OCF growth 5YN/A